Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FHKX3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $34,949
Award facts
- Contract value 100% obligated
- $34,948.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $34,948.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL auto-injector vials. This firm fixed-price delivery order, issued on January 26, 2026, with an ultimate completion date of February 17, 2026, was made without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The delivery will be performed at the vendor's Park Ridge, Illinois location.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion governmentwide acquisition strategy designed to streamline pharmaceutical supply chains for Department of Defense medical facilities worldwide. DMS Pharmaceutical Group holds a single-award prime vendor contract valued at $499,999,999 with a completion date of December 31, 2036, authorizing DLA to issue delivery orders for comprehensive pharmaceutical products including biologics, prescription medications, and medical consumables to support military healthcare operations globally. The company's established performance on numerous delivery orders since October 2025 demonstrates its capability to fulfill specialized pharmaceutical requirements across diverse therapeutic categories for the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FHKX3?
SPE2DR26FHKX3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 26, 2026.
How much is contract SPE2DR26FHKX3 worth?
The government has obligated $34,949 on SPE2DR26FHKX3.
Is contract SPE2DR26FHKX3 an order under another contract?
Yes. SPE2DR26FHKX3 is a delivery order under SPE2DR25D9222, an indefinite delivery contract.
Was contract SPE2DR26FHKX3 competed?
The extent of competition for SPE2DR26FHKX3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award